Startup Spotlight

The rising tide of antimicrobial resistance (AMR) is recognised as one of the major hurdles of the 21st century, being predicted to cause more deaths worldwide than cancer within the next 25 years [5]. Our overuse of antibiotic agents is driving the evolution of novel antimicrobial-resistant bacterial strains across both agricultural and healthcare sectors. Humanity is fighting a losing battle against billions of years of bacterial evolution. To keep in this fight, we need to come up with more innovative solutions within the field of antimicrobial biotechnology. 

May 2, 2024

PentaBind, a biotech start-up from London, aims to drug the undruggable, targeting diseases that have long been considered beyond the reach of conventional drug discovery methods. Recognising that only 15% of the human proteome has been effectively targeted by existing drugs [2], they are pioneering a novel therapeutic approach that combines the high specificity of aptamers with the power of artificial intelligence (AI).

May 2, 2024

In the quest to revolutionise cancer diagnosis, BioMavericks emerged amidst the COVID-19 crisis, recognizing a crucial gap in advanced sequencing methods for cancer detection. Their ground-breaking in vitro diagnostic tool, fuelled by proprietary biomarkers, with a sensitivity and specificity of over 97% promises exceptional accuracy in detecting prevalent cancers.

May 2, 2024